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Abstract
Background: The standard care in patients with a painful osteoporotic vertebral compression fracture (VCF) is
conservative therapy. Percutaneous vertebroplasty (PV), a minimally invasive technique, is a new treatment option.
Recent randomized controlled trials (RCT) provide conflicting results: two sham-controlled studies showed no
benefit of PV while an unmasked but controlled RCT (VERTOS II) found effective pain relief at acceptable costs. The
objective of this study is to compare pain relief after PV with a sham intervention in selected patients with an
acute osteoporotic VCF using the same strict inclusion criteria as in VERTOS II. Secondary outcome measures are
back pain related disability and quality of life.
Methods: The VERTOS IV study is a prospective, multicenter RCT with pain relief as primary endpoint. Patients with
a painful osteoporotic VCF with bone edema on MR imaging, local back pain for 6 weeks or less, osteopenia and
aged 50 years or older, after obtaining informed consent, are included and randomized for PV or a sham
intervention. In total 180 patients will be enrolled. Follow-up is at regular intervals during a 1-year period with a
standard Visual Analogue Scale (VAS) score for pain and pain medication. Necessary additional therapies and
complications are recorded.
Discussion: The VERTOS IV study is a methodologically sound RCT designed to assess pain relief after PV
compared to a sham intervention in patients with an acute osteoporotic VCF selected on strict inclusion criteria.
Trial registration: This study is registered at ClinicalTrials.gov., NCT01200277.
Background
Because of an aging population, osteoporosis and asso-
ciated fractures are becoming an important health
issue, especially in Western societies. The incidence of
a new vertebral compression fracture (VCF) in Europe
is, at age 50-79 years, 1% per year in women and 0.6%
per year in men and at age 75-79 years the incidence
is 2.9% per year in women and 1.4% per year in men
[1]. VCFs are associated with an increased incidence of
mortality and morbidity, including back pain, loss of
height, kyphotic deformity and a reduction in quality
of life [2].
Conservative therapy, bed rest, pain medication, phy-
siotherapy and bracing, is considered the standard care
in patients with symptomatic osteoporotic VCFs. Since
the introduction of percutaneous vertebroplasty (PV),
this minimal invasive therapy that involves injection of
bone cement in the fractured vertebral body, has gained
popularity to stabilize osteoporotic VCFs with resultant
relief of associated local back pain. PV is considered an
accepted pain therapy in many centres and acknowl-
edged as a useful additional option in the care for
patients with osteoporotic VCFs.
In 1984 PV was developed in France for the treatment
of painful aggressive vertebral angioma [3]. In the fol-
lowing years the indications for PV were expanded to
vertebral fractures caused by osteoporosis, trauma,
malignant or benign vertebral tumors and vertebral
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osteonecrosis. Presently, PV is most frequently per-
formed to treat patients with painful osteoporotic VCFs.
Many prospective and retrospective studies on PV
have been published and described a high clinical suc-
cess rate [4-12]. A recent systematic literature review
demonstrated the effectiveness of PV in 87% of patients
in terms of pain relief as well as a short- and long-term
improvement of physical function [13]. However, these
studies did not have a control group. In fact, the natural
course of pain in similar patients with a VCF was
unknown. Two non-randomised controlled trials have
been published comparing PV with conservative therapy
[14,15]. Both studies demonstrated a significant better
improvement in pain scores after PV on the short-term.
However, after 6 months no differences could be
demonstrated. VERTOS, the first randomised controlled
trial (RCT) with a limited group of 34 patients, reported
only on short-term results [16]. Longer term results
could not be obtained due to the cross-over of many
patients from optimal pain medication to PV. VERTOS
confirmed immediate pain relief and improvement of
mobility, function and stature after PV. The short-term
results after PV were significantly better compared to
pain medication in these patients with sub-acute or
chronic osteoporotic VCFs.
Recently, three RCTs concerning PV have been pub-
lished with conflicting results. Investigators in two ran-
domized controlled trials [17,18] concluded that there is
no benefit to PV over a sham placebo procedure invol-
ving the injection of local anesthetic into the area adja-
cent to the fracture. In the study by Buchbinder et al
[17], 78 patients with one or two painful osteoporotic
VCFs were randomized to receive either PV or a sham
procedure, which included infiltration of anesthetic into
the pedicular periosteum. The primary measured out-
come was overall pain at 3 months. Despite significant
reductions in overall pain in both groups, there was no
significant advantage of PV over the sham procedure. In
the study by Kallmes et al [18], 131 patients with one to
three painful osteoporotic VCFs were randomized to
undergo either PV or a simulated sham procedure,
which included infiltration of anesthetic into the perios-
teum of the posterior lamina. The primary outcomes
were scores on the modified Roland-Morris Disability
Questionnaire (RDQ) and average pain intensity during
the preceding 24 hours at 1 month. Treatment group
crossover was permitted at 1 month. At 1 month, there
was no significant difference between the two groups in
either the RDQ score or the pain rating. In the third
RCT, VERTOS II [19], PV was compared to optimal
conservative treatment in 202 patients who were 50
years or older, had vertebral compression fractures on
spine radiograph, had experienced back pain for 6 weeks
or less, and a visual analogue scale (VAS) score for pain
of 5 or more. The primary outcome was pain relief at 1
month and 1 year as measured by VAS score. The
authors concluded that in a subgroup of patients with
acute osteoporotic vertebral compression fractures and
persistent pain, percutaneous PV is effective and safe.
Pain relief after PV is immediate, is sustained for at
least a year, and is significantly greater than that
achieved with conservative treatment, at an acceptable
cost.
The most important differences between the two sham
studies and VERTOS II is patient selection. In the sham
studies both acute and chronic fractures were included
while in VERTOS II only acute fractures were eligible.
In addition, bone edema in the affected vertebra was
not a consistent inclusion criterion in the sham studies.
The sham studies lacked a control group without inter-
vention. The discordant results from the sham studies,
on the one hand, and VERTOS II, on the other hand,
have incited much debate [20-24]. Apparently clinicians
do still not know how to best treat their patients. The
objectives of this study is to evaluate the efficacy of
bone cement injection in PV for patients with acute
painful osteoporotic compression fractures, as compared
with a simulated placebo procedure without injection of
bone cement. We hypothesize that patients who had
undergone PV would report less pain at 1 day, 1 week
and 1, 3, 6 and 12 months (the primary outcomes) than
those in the sham control group. In addition, we
hypothesize that the back pain related disability is less
and the quality of life (QOL) is better of patients under-




VERTOS IV is a multicenter RCT concerning the treat-
ment of patients with a painful osteoporotic VCF.
Patients are recruited on the Radiology departments of
the participating hospitals and randomized to PV or a
simulated procedure. Upon obtaining informed consent
an independent central telephone operator completes the
randomisation procedure, using a computer program.
The maximum allowed unbalance (block size) is six, with
a maximum sample size of 84 for each participating cen-
tre. A total of 180 patients will be enrolled, 90 in each
group. This is based on the assumption of a 1.5 point dif-
ference in pain relief (VAS Score) and a 20% withdrawal
rate (a = 0.05 and b = 0.20, 7 measurement points). The
enrolment of patients will take place in four centres in
The Netherlands: St. Elisabeth Ziekenhuis in Tilburg,
Catharina Ziekenhuis in Eindhoven, Medisch Spectrum
Twente in Enschede and Albert Schweitzer Ziekenhuis in
Dordrecht. Randomization will start January 2011 with
an expected completion of enrolment by January 2013.
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There is a one-year follow-up, with the possibility of an
extended follow-up at two years.
The overall Institutional Review Board approval is
obtained at the St. Elisabeth Hospital in Tilburg
(NL33978.008.10). In addition, each participating cen-
tre will obtain a local Institutional Review Board
Approval. This study is registered at ClinicalTrials.gov.,
NCT01200277.
Patients
All patients, 50 years of age or older, referred for an X-
ray of the thoracic and/or lumbar spine, receive a short
clinical questionnaire. Patients diagnosed with a VCF
(Th5-L5), pain for six weeks or less and a Visual Analo-
gue Scale (VAS) score of five and higher are contacted
to participate in the study. After informed consent
patients undergo a magnetic resonance imaging (MRI)
scan of the spine, bone densitometry, blood sample
screening and a consultation of an internist. Patients
enrolled in the study comply with the following inclu-
sion criteria: (1) VCF on X-ray of the spine (minimal
15% loss of height) [25], (2) level of VCF Th5 or lower,
(3) back pain ≤ 6 weeks at time of X-ray, (4) ≥ 50 years
of age, (5) bone edema on MRI of the fractured verteb-
ral body, (6) focal tenderness on VCF level and (7)
decreased bone density T-scores ≤ -1. The exclusion cri-
teria are: (1) severe cardio-pulmonary condition, (2)
untreatable coagulopathy, (3) systemic or local infection
of the spine (osteomyelitis, spondylodiscitis), (4) sus-
pected alternative underlying disease (malignancy) (5)
radicular or caudal compression syndrome and (6) con-
tra-indication for MRI. All patients contacted to partici-
pate in the study are registered in order to obtain an
overview of the total patient population.
MRI protocol
MRI is performed prior to randomization using a 1, 1.5
or 3 Tesla MRI scanner. The following MRI sequences
are employed: sagittal T1 (TR 400 ms, TE 13 ms), T2
Turbo Spin Echo (TR 3500 ms, TE 120 ms) and STIR
(TR 2500 ms, TE 70 ms) and transverse T2 TSE (TR
2500 ms, TE 120 ms) at the level of the affected VCF.
Bone edema in the VCF is defined as increased signal
intensity at the STIR images and decreased signal inten-
sity at the T1 weighted images. The shape and grade of
every VCF is scored by two radiologists using the visual
semiquantitative system according to Genant (26).
When there is disagreement between both observers a
consensus meeting is held. The shape of the VCF is
classified as wedge, biconcave or crush, depending on
whether anterior, middle or posterior portion of verteb-
ral body is most diminished in height. The grade of
VCF is classified as a percentage of height reduction in
mild (15-25%), moderate (25-40%) and severe (>40%).
Interventions
The pre-procedural work-up consists of: ECG, chest X-
ray and blood sampling. One hour prior to the proce-
dure 2 g cefazolin is administered intravenously as pro-
phylaxis. Patients are brought to the angio suite, where
sterile preparation for surgery is performed. Using
fluoroscopic guidance, the practitioner infiltrates the
skin and subcutaneous tissues overlying the pedicle of
the target vertebra or vertebrae with 1% lidocaine and
infiltrates the periosteum of the pedicles with 0.25%
bupivacaine (marcaine). Patients are then randomly
assigned to undergo either the full PV procedure or the
sham intervention. For the PV procedure, 11-gauge or
13-gauge needles are passed into the central aspect of
the target vertebra or vertebrae. Bone cement is pre-
pared on the bench and injected under constant fluoro-
scopy into the vertebral body. Injection is stopped when
the cement reaches to the posterior aspect of the verteb-
ral body or leaks into an extraosseous space, such as the
intervertebral disk or an epidural or paravertebral vein.
During the sham intervention, verbal and physical cues,
such as pressure on the patient’s back, are given, and
the methacrylate monomer is opened to simulate the
odor associated with mixing of bone cement, but the
needle is not placed and cement is not injected. After
the procedure, all patients are monitored in the supine
position for 1 to 2 hours before discharge. Cross-over
will not be offered before 6 months after randomization.
Osteoporosis- and pain medication
All patients receive osteoporosis medication, such as
bisphosphonates together with supplemental calcium
and vitamin D. Pain medication demanded by the
patient is recorded. Analgesics are classified following
the WHO classification: (1) Paracetamol (acetamino-
phen), (2) Tramadol, (3) Tramadol and Paracetamol, (4)
Morphine. Non Steroid Anti Inflammatory Drugs
(NSAID) are only prescribed if patients are intolerant
for opiate-derivatives or when already used. Corrections
in dose and classification of pain medication are made if
necessary.
Clinical follow-up
An experienced nurse-practitioner requests patients to
complete a standard questionnaire before and at 1 day,
1 week, and 1, 3, 6 and 12 months after the procedure.
The questionnaire consist of the VAS score and ques-
tions about use of pain medication, pain location, and
pain type (primary outcomes). The VAS score is a pain
score ranging from 0 (no pain) to 10 (worst pain ever)
[26] Questions concerning use of pain medication, pain
location, and pain type are included. Secondary out-
comes are back pain related disability and QOL as mea-
sured with the Roland Morris Disability (RMD)
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Questionnaire and the Questionnaire of the European
Foundation for Osteoporosis (Qualeffo), respectively.
The Qualeffo is developed specifically for patients with
osteoporosis [27]. This questionnaire consists of 41
questions about: pain, physical function, social function,
general health perception, and mental function. The
Qualeffo score ranges from 0 (best quality of life) to 100
(worst quality of life). This questionnaire will be com-
pleted at five measurement moments (before and at 1,
3, 6, and 12 months after the procedure). The RMD
questionnaire is a disability questionnaire that measures
the functional status of patients with back pain [28,29].
The RMD will be completed at all measurement points.
Patients visit the internist at 1, 3, 6 and 12 months fol-
low-up. Patients receive a pain diary. Patients are asked
to complete the VAS score and use of analgesics is
recorded on a daily basis during the first month after
randomization.
Sample size considerations
Conform Kallmes et al. [18], we expect a 1.5 point dif-
ference in pain relief as measured by VAS score. Given
that there are seven measurement points (a = 0.05 and
b = 0.20) we need 142 patients in total). Assuming a
withdrawal rate of 20%, a total of 180 patients will be
enrolled, 90 in each group. We used G-Power to calcu-
late the sample size.
Statistical analysis
The data will be analysed according to the intention-
to-treat principle. Standard statistical techniques will
be used to describe characteristics of patients in both
groups. We will compare baseline characteristics in the
two treatment groups and if incomparability appears,
we will in secondary analysis, adjust for differences.
The primary outcome, significant pain relief, will be
compared between groups using analysis of variance
for repeated measures. If adjustment for possible base-
line incomparability is needed, analysis of covariance
will be done. Since we expect that the difference
between the two groups will become evident from 3
months onwards, the analysis will also be performed
only using scores before and 3, 6, and 12 months after
the procedure.
Conclusion
The VERTOS IV study is a RCT comparing PV with a
sham intervention using strict inclusion criteria designed
to assess pain relief in patients with an acute osteoporo-
tic VCF with mid-term follow-up.
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